Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 2, 2013, Pages 291-297

  Shook, David R ^a,b   Triplett, Brandon M ^a,b   Srinivasan, Ashok ^a,b   Hartford, Christine ^a   Dallas, Mari H ^a,b   Pillai, Asha ^a,b   Laver, Joseph ^a,b   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Allogeneic stem cell transplantation; Graft versus tumor; Pediatric soild tumor; Reduced intensity transplantation

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABLATION THERAPY; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CHIMERA; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; EVENT FREE SURVIVAL; EWING SARCOMA; GRAFT VERSUS HOST REACTION; HEPATOBLASTOMA; HODGKIN DISEASE; HUMAN; KIDNEY TUMOR; LONG TERM SURVIVAL; MALE; MELANOMA; NEPHROBLASTOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; RELAPSE; RHABDOMYOSARCOMA; SCHOOL CHILD; SIBLING; SOLID TUMOR; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHIMERISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84872619760     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.001     Document Type: Article

References (44)

1. Pui C.H., Pei D., Pappo A.S., et al. Treatment outcomes in black and white children with cancer: results from the SEER Database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol 2012, 30:2005-2012.
2. Rodriguez-Galindo C., Billups C.A., Kun L.E., et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002, 94:561-569.
3. Pappo A.S., Anderson J.R., Crist W.M., et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999, 17:3487-3493.
4. Katzenstein H.M., London W.B., Douglass E.C., et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol 2002, 20:3438-3444.
5. Garaventa A., Parodi S., De Bernardi B., et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009, 45:2835-2842.
6. Attarbaschi A., Dworzak M., Steiner M., et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 2005, 44:70-76.
7. Dome J.S., Liu T., Krasin M., et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002, 24:192-198.
8. Gardner S.L., Carreras J., Boudreau C., et al. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant 2008, 41:867-872.
9. Stiff P.J., Agovi M.A., Antman K.H., et al. High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant 2010, 16:525-532.
10. Kasper B., Lehnert T., Bernd L., et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004, 34:37-41.
11. Foncillas M.A., Diaz M.A., Sevilla J., et al. Engraftment syndrome emerges as the main cause of transplant-related mortality in pediatric patients receiving autologous peripheral blood progenitor cell transplantation. J Pediatr Hematol Oncol 2004, 26:492-496.
12. Barrett D., Fish J.D., Grupp S.A. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am 2010, 57:47-66.
13. Leung W., Chen A.R., Klann R.C., et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998, 22:971-979.
14. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
15. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
16. Satwani P., Harrison L., Morris E., et al. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005, 11:403-422.
17. Perez-Martinez A., Leung W., Munoz E., et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 2009, 53:120-124.
18. Koscielniak E., Gross-Wieltsch U., Treuner J., et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 2005, 23:242-244.
19. Inoue M., Nakano T., Yoneda A., et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003, 32:103-106.
20. Lucas K.G., Schwartz C., Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer 2008, 51:142-144.
21. Ohta H., Hashii Y., Yoshida H., et al. Allogeneic hematopoietic stem cell transplantation against recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2011, 33:e35-e38.
22. Porter D.L. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program 2011, 2011:292-298.
23. Demirer T., Barkholt L., Blaise D., et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008, 5:256-267.
24. Matthay K.K., Seeger R.C., Reynolds C.P., et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol 1994, 12:2382-2389.
25. Leung W., Campana D., Yang J., et al. High success of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011, 118:223-230.
26. Pulsipher M.A., Boucher K.M., Wall D., et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009, 114:1429-1436.
27. Inaba H., Handgretinger R., Furman W., et al. Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer 2006, 46:501-505.
28. Kasow K.A., Handgretinger R., Krasin M.J., et al. Possible allogeneic graft-versus-tumor effect in childhood melanoma. J Pediatr Hematol Oncol 2003, 25:982-986.
29. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
30. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
31. Langer T., Stohr W., Bielack S., et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 2004, 42:373-379.
32. Termuhlen A.M., Tersak J.M., Liu Q., et al. Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2011, 57:1210-1216.
33. Majhail N.S., Ness K.K., Burns L.J., et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007, 13:1153-1159.
34. Yu A.L., Gilman A.L., Ozkaynak M.F., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-1334.
35. Lundqvist A., Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J Immunother 2005, 28:281-288.
36. Rahir G., Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012, 61:751-759.
37. Baird K., Fry T.J., Steinberg S.M., et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant 2012, 18:698-707.
38. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011, 155:14-29.
39. Venstrom J.M., Zheng J., Noor N., et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009, 15:7330-7334.
40. Leung W., Handgretinger R., Iyengar R., et al. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007, 97:539-542.
41. Delgado D.C., Hank J.A., Kolesar J., et al. Genotypes of NK cell KIR receptors, their ligands, and Fc{gamma} receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010.
42. Berg S.L., Cairo M.S., Russell H., et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol 2011, 29:316-323.
43. Shook D.R., Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 2011, 78:409-415.
44. Ngo M.C., Rooney C.M., Howard J.M., Heslop H.E. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 2011, 20(R1):R93-R99.